Pharma Mar SA (ES:PHM) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pharma Mar SA’s partner, Luye Pharma Group, has secured conditional approval from China’s National Medical Products Administration for the commercialization of Zepzelca (lurbinectedin) to treat metastatic small cell lung cancer. This marks the drug’s approval in 17 global territories, reflecting its growing acceptance and potential market reach in the oncology sector. The approval is based on promising clinical study results, underscoring the drug’s efficacy and safety for patients in China.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.
